



In re Application of Examiner: Unknown HEATH et al. Group Art Unit: Unknown Serial No.: 08/699,716 Atty Docket: 003/029/SAP Filed: August 27, 1996 For: Recombinant F1-V Plague Vaccine Honorable Commissioner of Today's Date: January 16, 1997 Patents and Trademarks Washington, D. C. 20231 Sir: Transmitted for filing herewith are the following items: [x] Response to Notice to File Missing Part of Application [x] Declaration executed by omitted inventor Surcharge required [x] yes [] no amount \$130.00 [x] Computer readable form of Sequence Listing [x] Substitute sheets of drawings [x] Form PTO-1449 Petition to extend the original due date of to cover the date of this paper accompanied by the extension fee of: (Large/Small entity: [] 1 mo. \$110/\$55 1 2 mos. \$390/\$195 [] 3 mos. \$930/\$465 4 mos. \$1,470/735): Enter any previous extension fee paid since last Action-----subtract - \$ -0-Fee required \$130.00

Please charge the above fee and any missing or inadequate fee re this paper to Deposit Account No. 21-0380 for which purpose a duplicate copy of this sheet is attached.

[] Small entity verified statement filed [] herewith [] previously.

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner of Patents and Trademarks, Washington, D.C. 20231, on the date of January 16, 1997.

Respectfully submitted,


Sana A. Pratt, Reg. No. 39,441

Tel.: 301-294-9171 250 WJ 21-0380 01/28/97 08699716

25087 105 130.00CH

Ala o BEO

Larozco



Group Art Unit: Unknown

Serial No.: 08/699,716

Filed: August 27, 1996

For: Recombinant F1-V Plague Vaccine

January 16, 1997

RESPONSE TO NOTICE TO FILE MISSING PARTS

Honorable Commissioner of Patents and Trademarks Attention: Box Missing Parts Washington, D. C. 20231

Sir:

This is in response to the Notice to File Missing Parts dated December 18, 1996 in the subject application.

Herewith submitted is a Declaration form listing the names of all inventors and signed by David G. Heath, the omitted inventor. Entry of the executed declaration is respectfully requested.

Also submitted, as requested, are two sheets of drawings labeled with their respective number in substitution for the original two sheets of unlabeled drawings. The original and substitute drawings are the same and do not include new matter.

A computer readable form (CRF) copy of the "Sequence Listing" in the subject application is additionally submitted as requested. I hereby state that the computer readable form of the "Sequence Listing" is the same as the paper form of the sequence listing originally filed and contains no new matter.

In addition, submitted herewith is a PTO form 1449 disclosing 2 references considered relevant to the subject application, along with a copy of each reference. This Information Disclosure Statement is intended to be in full compliance with the rules but should the Examiner find any part of the requirements to have been omitted, prompt notice to that effect is requested with additional time under Rule 97(f) to enable applicants to comply.

Consideration of the foregoing and enclosures plus the return of a copy of the herewith form PTO-1449 with Examiner's initials in the left column per MPEP 609 are earnestly solicited.

Respectfully submitted,

Ву

John F. Moran Reg. No. 26,313

U.S. A. MRMC 504 Scott Street

Fort Detrick, MD 21702-5012

ATTN: MCMR-JA (John Moran-Patent Atty)

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to the

Commissioner of Patents Washington, D.C. 20231

on January 16, 1997.

Sana A. Pratt

Reg. No. 39,441

Application No.: CTO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CO ÉOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s): 1. This application clearly falls to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to these regulations, published at 1114 OG 29, May 15, 1990 and at 55 FR 18230, May 1, 1990. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 C.F.R. 1.821(c). 3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e). 4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing." 5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d). 6. The paper copy of the "Sequence Listing" is not the same as the computer readable from of the "Sequence Listing" as required by 37 C.F.R. 1.821(e). **Applicant Must Provide:** An initial or substitute computer readable form (CRF) copy of the "Sequence Listing". An initial or substitute paper copy of the "Sequence Listing", as well as an amendment directing its entry into the specification.

For questions regarding compliance to these requirements, please contact:

For Rules Interpretation, call (703) 308-4216

1.825(b) or 1.825(d).

For CRF Submission Help, call (703) 308-4212

For Patentin software help, call (703) 308-6856

PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR RESPONSE

A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or